Physician profile
Mauricio Tohen
NPI 1326256561
$159,783.25
in general payments reported to CMS, 2019-2025
11 companies · $22K in 2025
The $22K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,267 · 2020: $23K · 2021: $15K · 2022: $24K · 2023: $48K · 2024: $25K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $80K · Travel and Lodging: $8,036 · Honoraria: $4,500 · Food and Beverage: $2,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $80,456.00 |
| Travel and Lodging | $8,036.40 |
| Honoraria | $4,500.00 |
| Food and Beverage | $2,066.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $65,425.36 | 2020-2025 | Lybalvi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33,416.07 | 2019-2025 | Abilify Asimtufii, Abilify Maintena |
| Merck Sharp & Dohme LLC | $15,933.94 | 2021-2024 | |
| H. Lundbeck A S | $14,547.40 | 2021-2023 | Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $8,366.85 | 2025 | |
| Neurocrine Biosciences, INC. | $6,300.00 | 2022 | |
| Abbvie INC. | $5,333.63 | 2023-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $3,780.00 | 2023-2024 | Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,105.00 | 2020-2021 | |
| Allergan, INC. | $2,000.00 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $1,575.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mauricio Tohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.